

Javier Fernández-Ruiz is a PhD in Biochemistry obtained in 1986 in the Complutense University, Madrid, Spain. He is currently Full Professor in the Department of Biochemistry and Molecular Biology, Faculty of Medicine, in such university. Together with his teaching activities in the areas of Neurochemistry and Neurobiology, both in Degree and Master, he has been working during the last 37 years in different diseases of the Central Nervous System, having authored 237 research articles and 43 review articles in international journals, with a H-index of 68. Also 42 chapters in national and international books and 6 international patents. He has given lectures at different national and international universities and research centers, as well as numerous presentations at national and international congresses. He is currently the Principal Investigator of the "Cannabinoids and Neurological Disorders" research group at the Complutense University, and also at two cooperative networks of excellence research in Spain: CIBERNED and IRYCIS. The main activity of this group is the study of the therapeutic potential of cannabinoids in several neurological diseases, mainly neurodegenerative, activity addressed to the design, synthesis and biological characterization of novel cannabinoids with neuroprotective profile, and to test their therapeutic efficacy at preclinical and clinical levels. They have also conducted research addressed to explore the contribution of endocannabinoid dysregulations in the pathogenesis of neurodegenerative disorders. They are collaborating with several national and international groups, and four pharmaceutical companies: GW Pharma, Emerald Health Pharmaceuticals, VivaCell Biotechnology Spain, Roche and Symrise. He has participated in numerous research projects, acting as PI in many of them, including 7 research contracts with pharma companies. He has acted as reviewer for journals such as Annals of Neurology, Biological Psychiatry, Brain, FASEB Journal, FEBS Letters, Glia, Journal of Neuroscience, Nature Reviews Neuroscience, Neurobiology of Disease, Neuropharmacology, Neuroscience, PNAS, Trends in Pharmacological Sciences and others. He has been a member, representing the UCM, in the IRYCIS Governor Committee (2011-2017), and is currently a member in the Scientific Advisor Committee of the pharma companies Emerald Health Biotechnology-Spain and Linneo Health (formerly Alcaliber), and a member of the Editorial Board in the British Journal of Pharmacology. He has been President of the International Cannabinoid Research Society (ICRS) (2002-2003) and member of its Executive Committee (2001-2004), as well as a founding member of the Spanish Cannabinoid Research Society (SEIC) and member of its Executive Committee (2000-2013) serving as President during 2007-2011.